Alector, Inc. (NASDAQ:ALEC – Get Free Report) has been given a consensus rating of “Hold” by the nine research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $3.40.
ALEC has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. UBS Group restated a “neutral” rating and set a $1.50 target price on shares of Alector in a report on Tuesday. Finally, Morgan Stanley raised their target price on shares of Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a research report on Tuesday.
View Our Latest Report on Alector
Insider Transactions at Alector
In other news, CEO Arnon Rosenthal sold 72,606 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $193,131.96. Following the completion of the transaction, the chief executive officer directly owned 2,294,600 shares in the company, valued at $6,103,636. This represents a 3.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Neil Berkley sold 29,251 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $77,807.66. Following the completion of the transaction, the chief financial officer owned 350,649 shares of the company’s stock, valued at $932,726.34. The trade was a 7.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 111,303 shares of company stock valued at $295,633. Company insiders own 8.30% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in ALEC. Nantahala Capital Management LLC bought a new stake in shares of Alector during the 2nd quarter worth approximately $8,679,399. Public Employees Retirement System of Ohio acquired a new position in Alector during the second quarter worth $241,000. Bank of America Corp DE acquired a new position in Alector during the second quarter worth $287,000. Elmind Capital LP bought a new stake in Alector during the second quarter worth $1,809,000. Finally, ADAR1 Capital Management LLC bought a new stake in Alector during the second quarter worth $5,796,000. Institutional investors and hedge funds own 85.83% of the company’s stock.
Alector Stock Down 9.0%
NASDAQ:ALEC opened at $1.81 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.26 and a current ratio of 5.26. The company has a market cap of $202.10 million, a PE ratio of -1.65 and a beta of 0.62. Alector has a 52-week low of $1.09 and a 52-week high of $3.40. The stock has a 50-day simple moving average of $2.05 and a 200 day simple moving average of $2.03.
Alector (NASDAQ:ALEC – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%.The business had revenue of $3.32 million for the quarter, compared to analyst estimates of $1.71 million. On average, sell-side analysts expect that Alector will post -0.87 EPS for the current fiscal year.
Key Alector News
Here are the key news stories impacting Alector this week:
- Positive Sentiment: Genentech will receive exclusive global rights to develop and commercialize AL050, Alector’s investigational brain-penetrant GCase enzyme replacement therapy for Parkinson’s disease and other neurodegenerative conditions. The program uses Alector’s proprietary Alector Brain Carrier platform. Alector Genentech licensing agreement
- Positive Sentiment: The deal includes a $100 million upfront payment and potential milestone payments that could bring the total value to approximately $1.27 billion. The upfront cash is particularly important for Alector, whose operations remain heavily loss-making. Genentech pays Alector for Parkinson’s prospect
- Neutral Sentiment: Alector shares initially rose sharply following the announcement, reflecting investor enthusiasm that Roche will fund and advance the Parkinson’s program. However, the headline $1.27 billion figure is not guaranteed and depends on successful research, clinical development, regulatory approval and commercialization. Alector shares after Roche licensing deal
- Negative Sentiment: The program is described as preclinical, leaving substantial scientific, clinical and regulatory risk before any milestone payments or product revenue are realized. This may have encouraged profit-taking after the initial rally. Alector stock response to Genentech deal
- Negative Sentiment: Unusually heavy put-option activity was reported, with 20,569 puts purchased versus average daily volume of roughly 340. While options flow does not establish a fundamental change, it signals heightened downside hedging or bearish speculation and may add volatility.
Alector Company Profile
Alector, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s approach, known as immuno-neurology, seeks to use the immune system to protect brain health and address biological mechanisms involved in conditions such as Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease.
Alector’s pipeline includes latozinemab, an antibody designed to increase levels of progranulin, a protein associated with the health and function of brain cells.
Further Reading
- Five stocks we like better than Alector
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.
